Shionogi Of Japan Working To Become Multinational
This article was originally published in PharmAsia News
Japan's Shionogi has ambitious plans to transform itself into a multinational company in the pharmaceutical industry. It has five drugs in middle- to late-stage clinical trials in its three areas of concentration - infectious diseases and metabolic and pain syndromes. A new Shionogi administration took over the company April 1 and set goals for itself through its 2009 fiscal year. In the past the company has relied on ties to other multinationals for most of its earnings, but patents on most of those drugs are due to expire within the next 10 years. Already in the current fiscal year, Shionogi has seen its U.S. sales out-number sales in its home country. (Click here for more - a subscription may be required
You may also be interested in...
Procter & Gamble, through its UK wellness subsidiary Nature's Best, is on-trend with new vegan vitamin D3 and iron supplements. Nature's Best has also launched three other vitamin D3 products in the country, as well as an ashwagandha supplement.
The MHRA has updated its guidance on regulatory flexibilities for medical devices and medicinal products resulting from COVID-19 to highlight how its approach differs from the EU.
The Swiss company is planning a US trial of CBSO, the first transcatheter septal occluder with a bioresorbable, metal-free frame.